How Patent Expirations, Pricing Pressure and R&D Costs Are Reshaping Biopharma

Where Is Value and Growth? The New Economics of Biopharma

The Coming Patent Cliff Is Really a Timing Problem

For much of the past three decades, large biopharmaceutical companies relied on a familiar economic model: a small number of blockbuster products, a global commercial organization, and sufficient pricing power to offset delays in the development of new products. That model is becoming less reliable. Many large primary-care markets are mature, while personalized and precision medicines are expanding. As a result, the period from 2026 to 2030 is likely to require a fundamental reconsideration of how companies create, protect, and replace value.

The approaching loss of patent protection is central to this challenge. Evaluate has estimated that approximately $300 billion in branded-drug revenue could be exposed by 2030, an amount equal to roughly one-sixth of industry revenue.¹˒² DelveInsight estimates that nearly 200 branded medicines, including 69 blockbusters, will lose exclusivity between 2025 and 2030.³ The effects will therefore extend across the sector rather than remain confined to a few companies.

If you’re familiar with generic drug erosion, you’ll know the consequences can occur quickly. DelveInsight reports that, in some categories, branded-product revenue has declined by 80% to 90% within 12 to 18 months after generic or biosimilar competition begins, although the rate varies by market, distribution channel, and prescribing behavior.⁵ Companies must consequently replace products that may have required a decade or more to develop, even though the associated revenue can diminish within several quarters.

The patent cliff is therefore a problem of timing as well as scale. A company may anticipate the end of exclusivity for years but still lack enough time to develop a replacement that is clinically differentiated, approved by regulators, reimbursed by payers, and commercially established. The costs of discovery to market are escalating rapidly. Deloitte’s 16th annual biopharma innovation report, covering 2025 data, reports $2.671 billion as an average cost-per-asset measure from discovery to launch for its late-stage pipeline cohort, up from $2.229 billion in 2024.⁶ This combination of expense and limited time makes patent expiration a broad capital-allocation issue rather than a matter for intellectual-property and portfolio teams alone.

Leadership teams must decide where to concentrate therapeutic investment, how to use licensing and acquisitions, which products justify life-cycle extensions, and when to discontinue programs that are unlikely to produce meaningful value. Recent merger speculation illustrates the intensity of this search for scale and replacement growth.⁴ Companies that depend heavily on one or two franchises face the greatest urgency because a single unsuccessful development program or transaction may leave a substantial revenue gap.

Price Is No Longer the Whole Argument

Pricing pressure in the United States has become part of the commercial environment rather than a secondary concern. The Centers for Medicare & Medicaid Services (CMS) finalized negotiated prices for the first cycle of the Medicare Drug Price Negotiation Program, with those prices taking effect in 2026. The agency considered information that included research and development costs, federal support, production and distribution costs, and market evidence.⁷ CMS subsequently announced a third negotiation cycle involving 15 additional Part B and Part D drugs, with negotiated prices scheduled to take effect in 2028.⁸

KFF calculated that the 15 drugs selected for negotiation in 2026 accounted for $27 billion in gross Medicare spending from November 2024 through October 2025.⁹ This concentration explains why a relatively small number of products are receiving close attention from public payers.

These developments change how companies must demonstrate value. Comparative clinical evidence, health outcomes, and reimbursement considerations increasingly need to inform development strategy before approval. Similar pressures are emerging in Europe through joint clinical assessment, where evidence must be useful across countries with different payment systems and patterns of care.

The traditional separation among clinical development, regulatory affairs, and market access is therefore less practical. Trial design itself becomes a strategic decision: a program may obtain regulatory approval yet create limited commercial value if it does not provide persuasive comparative evidence for payers and clinicians. In some cases, a longer or more carefully designed program may produce a stronger reimbursement position than a faster program focused mainly on approval.

R&D Economics Are Becoming Less Forgiving

Research and development economics were already becoming more difficult before pricing pressure increased. Late-stage assets are expensive to acquire, and complex therapeutic approaches require specialized manufacturing, clinical, and regulatory capabilities. Smaller biotechnology companies often face limited funding periods and must focus on a small number of milestones rather than finance an entire development program.

This environment has created a more selective market for innovation. Large companies seek differentiated products, but credible late-stage opportunities are scarce and costly. Smaller companies often need partners, sometimes from a weak negotiating position. The important question is not simply whether a transaction adds another asset, but whether it addresses a defined scientific, commercial, or portfolio need.

The same discipline applies to internal research. Scientific breadth remains valuable, but capital markets often reward organizational focus. When each program requires substantial investment, not every indication or platform can be treated as equally strategic. Companies may perform better by defining clear criteria for continued investment and ending weak programs early, before they absorb additional time and capital.

Growth Will Look Narrower and More Deliberate

Biopharma is unlikely to face a shortage of scientific opportunity. It may, however, face shortages of time, convincing evidence, and available capital. Development costs, long timelines, and clinical attrition make broad and weakly differentiated portfolios difficult to sustain. About 90% of drug candidates that enter clinical trials never reach approval.

Growth during the next planning cycle may therefore depend less on replacing one blockbuster with another. It is more likely to come from portfolios that combine focused internal research, selective external innovation, strong evidence, and products capable of withstanding rapid loss of exclusivity and closer payer review. This approach may be less dramatic than the traditional blockbuster model, but it offers a more realistic basis for durable value creation.

Key Issues at a Glance

The Looming Patent Cliff

Companies must replace large revenue pools while defending value through loss of exclusivity.

• Concentrated LOE Pressure: A major wave of blockbuster expiries is compressing growth and margin headroom.
• Generic and biosimilar erosion: Uptake varies by market, channel and switching behavior, making erosion harder to forecast.
• Pipeline replacement: Internal pipelines alone cannot fill every gap on the required timeline.

Pricing and Access Pressure

The hurdle is no longer just price. It is proving value early enough to preserve access.

• Medicare Negotiation: Selected products face administered prices and shorter effective commercial runways.
• Part D Redesign: Manufacturer liability and plan economics change formulary and gross-to-net dynamics.
• Global HTA Evidence: EU joint clinical assessment raises the bar for coordinated comparative evidence.

R&D Economics

High cost, long cycle times and clinical attrition make broad, undifferentiated pipelines difficult to sustain. Sharp choices must be made.

• Development Costs and Failure: Complex programs consume capital for years before efficacy, safety and differentiation are established.
• Scarce Differentiated Assets: Competition for credible late-stage programs raises deal prices and execution risk.
• Capital Scarcity for Biotechs: Short runways force smaller firms to prioritize a narrow set of value inflection points.

Frequently Asked Questions

References

1. PharmaVoice. “Big Pharma Is Navigating a $300 Billion Patent Cliff.”
2. DelveInsight. “Pharma Patent Cliff.”
3. DelveInsight. “Pharma Patent Cliff.”
4. BioSpace. “Unlikely AstraZeneca-BMS Mega-Merger Would Be Largest Pharma Deal Ever.”
5. DelveInsight. “Pharma Patent Cliff.”
6. Deloitte. “Navigating the GLP-1 Boom: Measuring the Return from Pharmaceutical Innovation.”
7. Centers for Medicare & Medicaid Services. “Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026.”
8. Centers for Medicare & Medicaid Services. “CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation.”
9. KFF. “Key Facts About Medicare Drug Price Negotiation.”